Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness

• DOI: 10.37047/jos.2022-92714
• Publication Date: 2023-03-23T09:16:29Z
• Authors: Serdar KARAKAYA; Özgen Ahmet YILDIRIM; Şeyma IŞIK; Şebnem YÜCEL; İbrahim KARADAĞ

ABS TRACT Data on the management of Grade 3-4 visual disorders due to lorlatinib remain limited.We presented two cases Grade-4 vision loss lorlatinib.We interrupted and initiated a pulse steroid in these patients.In our first patient, function improvement was observed three days after treatment, with complete recovery at end month.However, second although returned extent limited from 3 m, no further noted.In both patients, continued reduced dose because favorable response improvement.In conclusion, early recognition interruption may be effective successful loss.Concurrent therapy also beneficial.